Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

IOL News

12/6/2024
BreakingEuropeIOLPresbyopiaRefractiveSurgical
Ophtec Receives CE Marking for Artiplus Phakic IOL, Targets Young Presbyopes
Ophtec Receives CE Marking for Artiplus Phakic IOL, Targets Young Presbyopes

Dutch company Ophtec announced Nov. 18 that it had gained CE Mark approval for its Artiplus phakic intraocular lens (IOL). The company said the lens offered a solution for relatively young presbyop...

11/15/2024
BreakingCataractChinaDry EyeGlaucomaIOLLaserRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

11/14/2024
DiagnosticIOLNewsletterOCTRegulation
Select US FDA Approvals and Clearances in October 2024
Select US FDA Approvals and Clearances in October 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in October 2024, according to the agency’s database. Apple gained clearance for its Digital Prism ...

11/14/2024
AAOCataractIOLMeetingNewsletterPremiumSurgical
New Trifocal IOLs Expected to Help the US Resume PC-IOL Growth
New Trifocal IOLs Expected to Help the US Resume PC-IOL Growth

Bausch + Lomb’s enVista Envy and J&J Vision’s Odyssey are two new trifocal IOLs that were shown at the 2024 AAO meeting in Chicago. They are expected to help reverse the decline in trifocal IOL sal...

11/1/2024
BreakingIOLPharmaRetinaRevenue
Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis
Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis

Regeneron of Tarrytown, New York, reported Oct. 31 that its Q3-2024 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.54 billion, a 3 percent increa...

10/25/2024
BreakingIOLPharmaRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Roche and J&J Vision
Q3-2024 Ophthalmic Revenue Roundup for Roche and J&J Vision

Swiss company Roche reported Oct. 23 that Q3-2024 Vabysmo sales were CHF 1 billion ($1.15 billion, converted on Oct. 23, 2024), a 59 percent increase over CHF 656 million in Q3-2023. The company sa...

10/18/2024
BreakingCataractIOLRegulationSurgical
Bausch + Lomb Gains US FDA Approval of enVista Envy Trifocal IOL
Bausch + Lomb Gains US FDA Approval of enVista Envy Trifocal IOL

Bausch + Lomb reported Oct. 14 that the US FDA had approved itsenVista Envy trifocal intraocular lens. The lens is available on a limited basis in the US and will be launched more broadly in 2025. ...

10/15/2024
ESCRSEuropeIOLMeetingNewsletter
ESCRS Congress Celebrates 75th Anniversary of First IOL Implantation
ESCRS Congress Celebrates 75th Anniversary of First IOL Implantation

The 2024 ESCRS congress celebrated the 75th anniversary of Sir Harold Ridley, MD, implanting the first intraocular lens by telling his story and describing the developments that have occurred since...

10/15/2024
ESCRSEuropeIOLMeetingNewsletter
2024 ESCRS Congress Puts Spotlight on Latest IOL Designs
2024 ESCRS Congress Puts Spotlight on Latest IOL Designs

New and recently launched IOLs took the spotlight in presentations and on the exhibit floor at the 2024 ESCRS congress. These lenses included the Rayner RayOne Galaxy trifocal, the BVI Serenity Mon...

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/11/2024
BreakingCataractClinical TrialIOLRegulation
Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL
Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL

UK-based Rayner reported Oct. 1 that the first RayOne Galaxy lenses had been implanted in the US as part of an FDA investigational device exemption (IDE) study. Rayner describes the Galaxy, a trifo...

9/19/2024
CataractIOLNewsletterPremiumSurgical
Weekly Surgeon Poll, September 2024
Weekly Surgeon Poll, September 2024

8/30/2024
BreakingCataractESCRSEuropeIOLSurgical
Rayner to Roll Out First Spiral IOL at 2024 ESCRS Congress
Rayner to Roll Out First Spiral IOL at 2024 ESCRS Congress

UK-based Rayner reported Aug. 26 that it was set to launch the first spiral intraocular lens models—the RayOne Galaxy and Galaxy Toric—at the 2024 ESCRS Congress, set for Sept. 6-10 in Barcelona, S...

8/30/2024
BreakingCataractIOLRevenueSingle-UseSurgical
Alcon Reports Q2-2024 Net Sales of $2.5 Billion
Alcon Reports Q2-2024 Net Sales of $2.5 Billion

Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...

8/21/2024
CataractIOLNewsletterRegulationRetina
Select US FDA Approvals and Clearances in July 2024
Select US FDA Approvals and Clearances in July 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in July 2024, according to the agency’s database. Topcon gained clearance for its Maestro2 OCT in c...

8/9/2024
BreakingCataractDry EyeGlaucomaIOLRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

8/2/2024
BreakingCornealDiagnosticDry EyeGlaucomaIOLLaserRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

7/23/2024
Clinical TrialDry EyeGene TherapyIOLNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2024
Clinical Trial Updates for Ophthalmic Candidates, July 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

7/19/2024
BreakingCataractIOLRevenueSurgical
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million

J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...

6/24/2024
ChinaIOLNewsletterRegulation
Volume-Based Procurement Could Upend China’s IOL Market
Volume-Based Procurement Could Upend China’s IOL Market

Alcon offered big discounts in China’s public sector centralized volume-based procurement (VBP) cycle for intraocular lenses (IOLs). The company’s low bids in seven of the eight bidding categories ...

6/24/2024
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume
Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.0 percent in Q1-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

6/24/2024
DiagnosticFundusGlaucomaIOLNewsletterOCTRegulationSurgical
Select US FDA Approvals and Clearances in May 2024
Select US FDA Approvals and Clearances in May 2024

The US FDA granted six clearances through the ophthalmic device division using the 510(k) pathway in May 2024, according to the agency’s database. Reichert gained market clearance for its new hand-...

6/24/2024
IOLNewsletterRegulation
Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL
Bausch + Lomb Receives Health Canada Approval  for EnVista Envy Trifocal IOL

Bausch + Lomb announced May 28 that Health Canada had approved the enVista Envy trifocal intraocular lens (IOL). It’s the first approval for the new lens. The Envy was expected to be available in C...

6/24/2024
DiagnosticIOLNewsletterPremium
Weekly Surgeon Poll, June 2024
Weekly Surgeon Poll, June 2024

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

6/14/2024
BreakingCataractEuropeIOLRegulationSurgical
Nidek Gains CE Marking for Preloaded IOL Injector System
Nidek Gains CE Marking for Preloaded IOL Injector System

Japan’s Nidek announced June 10 that it had received CE marking for the NP-1/NP-1C preloaded IOL injection system. The system is preloaded with the Aktis aspheric hydrophobic soft acrylic lens, whi...

5/31/2024
BreakingCataractIOLOcular CancerRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore

Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...

5/31/2024
BreakingCataractIOLRegulationSurgical
Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL
Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL

Bausch + Lomb announced May 28 that Health Canada had approved the enVista Envy trifocal intraocular lens (IOL). It’s the first approval for the new lens. The Envy is expected to be available in Ca...

5/22/2024
AICataractDiagnosticFundingGene TherapyGlaucomaIOLNewsletterRetina
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

5/22/2024
Clinical TrialGene TherapyIOLIndustryMeetingNewsletterRetinaStudy
Ophthalmic Companies Use ARVO Meeting to Boost Research
Ophthalmic Companies Use ARVO Meeting to Boost Research

Many companies participate in ARVO’s annual meeting to catch the attention of external researchers and propel their research program or clinical trials forward. Two such companies in 2024 were John...

4/24/2024
Data SecurityIOLNewsletter
Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

4/24/2024
DigitalIOLNewsletterRegulation
Select US FDA Approvals and Clearances in March 2024
Select US FDA Approvals and Clearances in March 2024

The US FDA granted three clearances through the ophthalmic device division using the 510(k) pathway in March 2024, according to the agency’s database. Cylite received clearance for its HP-OCT. The ...

4/24/2024
ASCRSCataractIOLNewsletterSurgical
J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting
J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting

Johnson & Johnson Vision launched and touted the Tecnis Odyssey presbyopia-correcting IOL at a number of venues at the 2024 ASCRS meeting. Blake Williamson, MD, and Priya Matthews, MD, described J&...

4/24/2024
ASCRSCataractIOLNewsletterSurgical
RxSight Launches the LAL+ IOL with Large ASCRS Program
RxSight Launches the LAL+ IOL with Large ASCRS Program

RxSight continued to build momentum for its post-op adjustable IOL with a big presence at the 2024 ASCRS meeting, including an Eyecelerator presentation on the new LAL+ and 14 speaker sessions at t...

4/24/2024
CataractIOLNewsletterRegulationSurgical
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

4/24/2024
CataractIOLNewsletterPremiumSurgical
Weekly Surgeon Poll, April 2024
Weekly Surgeon Poll, April 2024

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/19/2024
BreakingCataractIOLSurgical
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan

BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...

4/19/2024
BreakingCataractIOLRevenueSurgical
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million

J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...

4/19/2024
BreakingCataractData SecurityIOLSurgical
Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

4/12/2024
BreakingCataractIOLSurgical
Rayner Marks Sale of 5 Millionth RayOne IOL
Rayner Marks Sale of 5 Millionth RayOne IOL

UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...

3/29/2024
BreakingCataractEnvironmentIOLSurgical
Rayner Updates Packaging to Lessen Impact on Environment
Rayner Updates Packaging to Lessen Impact on Environment

UK-based Rayner announced March 25 that it would update its packaging to reduce the company’s carbon footprint and improve ease of use for customers. Rayner said the new packaging will replace pape...

3/22/2024
BreakingCataractIOLIndiaSurgical
Alcon Launches Clareon PC-IOLs in India
Alcon Launches Clareon PC-IOLs in India

Alcon announced March 12 that it had launched presbyopia-correcting intraocular lenses (IOLs) in India made of the Clareon glistening-free material. The Clareon platform is available in India in tw...

3/21/2024
CataractGlaucomaIOLNewsletterRetina
Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume
Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume

----- Refractive: -12.1 IOL: 5.4 Glaucoma: 4.8 Retina: -4.4 ----- US ophthalmologists reported that ophthalmic procedures decreased 1.8 percent in Q4-2023 compared with the same quarter in 2022, ac...

3/21/2024
CataractIOLNewsletterPremiumSurgical
Robust Premium IOL Revenue Growth Expected to Continue Through 2029
Robust Premium IOL Revenue Growth Expected to Continue Through 2029

The global intraocular lens market has shown strong growth during the past seven years, increasing from $3.8 billion in 2017 to $5.8 billion in 2023, for a compound annual growth rate of nearly 8 p...

3/21/2024
CataractIOLIndiaNewsletterSurgical
Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations
Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations

Alcon reported March 6 that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) had surpassed more than 1 million implantations worldwide. According to...

3/21/2024
CornealDealsDry EyeIOLIndustryNewsletterRegulationRetina
March 2024 Ophthalmic News Briefs
March 2024 Ophthalmic News Briefs

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

3/15/2024
BreakingCataractIOLSurgical
Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations
Alcon’s Vivity EDOF IOL Reaches Milestone of 1 Million Implantations

Alcon reported March 6 that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) had surpassed more than 1 million implantations worldwide. According to...

3/8/2024
BiosimilarsBreakingIOLLaserOcular CancerRetinaRevenue
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen

UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...

3/1/2024
BreakingCornealDry EyeGlaucomaIOLRefractiveRetinaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

2/23/2024
BreakingCataractEuropeIOLMeetingSurgical
VSY Launches Enova Maestro Trifocal Toric Preloaded IOL at ESCRS Winter Meeting
VSY Launches Enova Maestro Trifocal Toric Preloaded IOL at ESCRS Winter Meeting

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

2/22/2024
CataractEuropeIOLNewsletterSurgical
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in EMEA Countries
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in EMEA Countries

Johnson & Johnson MedTech announced Feb. 15 that its Tecnis PureSee refractive presbyopia-correcting intraocular lens (IOL) is now available in select markets in Europe, the Middle East, and Africa...

2/22/2024
CataractEuropeIOLNewsletterSurgical
February 2024 Weekly Surgeon Poll: US vs. Western European Ophthalmologists
February 2024 Weekly Surgeon Poll: US vs. Western European Ophthalmologists

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/16/2024
BreakingCataractEuropeIOLSurgical
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in Select EMEA Countries
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in Select EMEA Countries

Johnson & Johnson MedTech announced Feb. 15 that its Tecnis PureSee refractive presbyopia-correcting intraocular lens (IOL) is now available in select markets in Europe, the Middle East, and Africa...

2/16/2024
BreakingChinaIOLRefractiveRevenueSurgical
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya

Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...

1/26/2024
BreakingGlaucomaIOLPharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox

Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....

1/23/2024
Dry EyeIOLNewsletterRefractive
2023 in Review: Bausch + Lomb Makes Big Moves, Adding Product Lines and Building Partnerships
2023 in Review: Bausch + Lomb Makes Big Moves, Adding Product Lines and Building Partnerships

Bausch + Lomb made a flurry of big moves in 2023, with product approvals, acquisitions, leadership changes, and strategic partnerships and collaborations following the company’s IPO in mid-2022. In...

1/26/2024
BreakingIOLRegulation
Rayner’s RayOne EMV Enhanced Monofocal IOL Receives Health Canada Approval
Rayner’s RayOne EMV Enhanced Monofocal IOL Receives Health Canada Approval

UK-based Rayner announced Jan. 23 that Health Canada had approved its RayOne EMV enhanced monofocal intraocular lens (IOL). The lens received US FDA approval in March 2021. Rayner said the RayOne E...

1/23/2024
CataractIOLNewsletter
Ophtec Launches Its Precizon Go Enhanced Monofocal Lens
Ophtec Launches Its Precizon Go Enhanced Monofocal Lens

Dutch company Ophtec announced Dec. 11 the launch of its Precizon Go intraocular lens (IOL), a “monofocal plus” lens designed to provide distance and enhanced intermediate vision. Precizon Go featu...

1/23/2024
Dry EyeIOLLaserNewsletterRegulation
Select US FDA Approvals and Clearances in December 2023
Select US FDA Approvals and Clearances in December 2023

The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in December 2023, according to the agency’s database. RetMap gained market clearance for its RM El...

12/20/2023
BreakingCataractEuropeIOLSurgical
Ophtec Launches Precizon Go Enhanced Monofocal IOL
Ophtec Launches Precizon Go Enhanced Monofocal IOL

Dutch company Ophtec announced Dec. 11 the launch of its Precizon Go intraocular lens (IOL), a “monofocal plus” lens designed to provide distance and enhanced intermediate vision. Precizon Go featu...

12/14/2023
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 6.4 Percent Decline in Q3-2023 Procedure Volume
Ophthalmologists Report 6.4 Percent Decline in Q3-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.4 percent in Q3-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

12/15/2023
BreakingDiagnosticIOLRevenueSurgical
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $1.67 Billion
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $1.67 Billion

Carl Zeiss Meditec reported Dec. 12 that ophthalmology revenue for is full fiscal year 2022/2023, which ended Sept. 30, was €1.58 billion ($1.67 billion, converted Sept. 30), a 7.3 percent increase...

12/14/2023
CataractIOLNewsletterRefractiveSurgical
Weekly Surgeon Poll, December 2023
Weekly Surgeon Poll, December 2023

12/8/2023
BreakingCataractGlaucomaIOLIndustry
SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer
SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer

SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...

11/21/2023
CataractIOLNewsletterPremiumSurgical
US Dominance of Premium Cataract Surgery Market Expected to Grow
US Dominance of Premium Cataract Surgery Market Expected to Grow

New technology and competition are expected to further expand the dominance of the US premium cataract surgery (PCS) market over the next five years. The US is already the dominant PCS market globa...

11/21/2023
AAOCataractIOLMeetingNewsletterSurgical
RxSight Announces Controlled Launch of LAL+ with Extended EDOF Functionality
RxSight Announces Controlled Launch  of LAL+ with Extended EDOF Functionality

RxSight—already the fastest growing IOL company in the US—is conducting a controlled launch of an additional version of the Light Adjustable Lens (LAL), referred to as the LAL+. Stephen Slade, MD, ...

11/21/2023
AAOCataractIOLMeetingNewsletterSurgical
Surgeons Compare Trifocal and EDOF IOLs During AAO Refractive Day
Surgeons Compare Trifocal and EDOF IOLs During AAO Refractive Day

Trifocal IOLs went head-to-head with extended depth of focus lenses during the 2023 AAO Refractive Day program as Damien Gatinel, MD, PhD (France), advocated for trifocal models and Douglas Koch, M...

11/21/2023
CataractIOLNewsletterSurgical
Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US
Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US

Bausch + Lomb announced Oct. 18 the US launch of its enVista Aspire monofocal and toric intraocular lenses with intermediate-optimized optics. The company said that, unlike conventional spherical m...

11/17/2023
BreakingCataractDry EyeIOLOcular CancerPharmaRevenue
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others

UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...

11/10/2023
BreakingDry EyeGlaucomaIOLLaserRevenue
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...

10/27/2023
BreakingCataractIOLSurgical
Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US
Bausch + Lomb Launches enVista Aspire Intermediate-Optimized Monofocal and Toric IOLs in US

Bausch + Lomb announced Oct. 18 the US launch of its enVista Aspire monofocal and toric intraocular lenses with intermediate-optimized optics. The company said that, unlike conventional spherical m...

10/24/2023
ESCRSIOLMeetingNewsletter
Five New PC-IOLs Push Total to Nearly 100 in Europe
Five New PC-IOLs Push Total to Nearly 100 in Europe

European cataract surgeons now have access to nearly 100 presbyopia-correcting IOLs, after five new lenses made their debut at the 2023 congress of the European Society of Cataract and Refractive S...

10/24/2023
CataractDry EyeESCRSGlaucomaIOLMeetingNewsletterRegulationSurgical
Buzzworthy Topics at the 2023 ESCRS Congress
Buzzworthy Topics at the 2023 ESCRS Congress

Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...

10/24/2023
IOLMeetingNewsletterPresbyopiaRefractive
ISOP Meeting Analyzes ‘Phacorestoration’ and ‘Presbyopia Botox’
ISOP Meeting Analyzes ‘Phacorestoration’ and ‘Presbyopia Botox’

The International Society of Presbyopia highlighted new treatment approaches that come with some interesting names. The conference was held Sept. 7 at the Vienna Marriott Hotel in Vienna, Austria. ...

10/24/2023
CataractClinical TrialDealsDiagnosticDry EyeGene TherapyGenericsIOLIndustryMicroscopesNewsletterOcular CancerRegulationRetina
October 2023 Ophthalmic News Briefs
October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

10/13/2023
BreakingChinaDealsIOL
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market

China’s AffaMed Technologies announced Oct. 10 that it had entered into an agreement with SIFI, of Italy, to manufacture, develop, and commercialize SIFI’s Evolux enhanced monofocal intraocular len...

10/13/2023
BreakingCataractIOLIndustrySurgical
HumanOptics Appoints Alexander Berka as New CEO
HumanOptics Appoints Alexander Berka as New CEO

HumanOptics, of Erlangen, Germany, announced Oct. 4 that it had named Alexander Berka as its chief executive officer. HumanOptics markets an artificial iris and the Triva, Torica, and Aspria intrao...

9/21/2023
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 4.9 Percent Decrease in Q2-2023 Procedure Volume
Ophthalmologists Report 4.9 Percent Decrease in Q2-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 4.9 percent in Q2-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

9/21/2023
GlaucomaIOLNewsletterRetina
Select US FDA Approvals and Clearances in August 2023
Select US FDA Approvals and Clearances in August 2023

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in August 2023, according to the agency’s database. RxSight received clearance for a new IOL injec...

8/22/2023
CataractIOLNewsletterRegulation
Select US FDA Device Approvals and Clearances in July 2023
Select US FDA Device Approvals and Clearances in July 2023

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in July 2023, according to the agency’s database. Altris received clearance for its image managemen...

8/22/2023
CataractCornealDry EyeFundingGene TherapyIOLNewsletterPharmaRetinaSurgical
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

8/22/2023
CataractClinical TrialGlaucomaIOLNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2023
Clinical Trial Updates for Ophthalmic Candidates, August 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/22/2023
AICataractDealsGlaucomaIOLIndustryNewsletterPharmaRegulationRetinaSingle-Use
August 2023 Ophthalmic News Briefs
August 2023 Ophthalmic News Briefs

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

8/10/2023
AllergyBreakingCataractGlaucomaIOLRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others

Japan-based Hoya Corporation announced July 31 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2023—the first quarter of its fiscal yea...

7/28/2023
BreakingDry EyeGlaucomaIOLLaserRetinaRevenue
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others

Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...

7/28/2023
BreakingIOLIndustry
BVI Expands IOL Manufacturing Capacity with New Facility in Belgium
BVI Expands IOL Manufacturing Capacity with New Facility in Belgium

BVI Medical announced July 18 the opening of its new, state of the art intraocular lens manufacturing facility in Liège, Belgium. The company, headquartered in Waltham, Massachusetts, said the new ...

7/25/2023
IOLNewsletterRegulation
BVI Launches FineVision HP Trifocal Lens in Japan
BVI Launches FineVision HP Trifocal Lens in Japan

BVI Medical reported June 20 that it had launched its FineVision HP intraocular lens in Japan. The hydrophobic trifocal lens is the third generation of the FineVision platform, which developer Phys...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more